The European Prevention of Alzheimer’s Dementia (EPAD), a major Europe-wide initiative aiming to improve the understanding of the early stages of Alzheimer’s disease, has announced the external release of its second wave of data including the baseline data from the first 1.500 research participants (V1500.0).
The previous V500.0 data release went into open access in November 2019. Data are provided via secure online tools in order to facilitate collaboration between people and teams with similar research aims. Academic researchers and institutions from all over the world are invited to begin the application process. To access the data, you will need to make an online request by visiting the EPAD LCS Research Access Process webpage, where you will find a variety of resources to support your research.
“This most recent and substantial data release from the EPAD cohort will undoubtedly have a major impact on our understanding of Alzheimer’s disease at very early stages of its development. Releasing this data to the global research community for free and rapid access marks a major milestone for EPAD and will hopefully set a standard for open data access that will ultimately benefit the millions of people worldwide at risk of developing Alzheimer’s dementia.” said Craig Ritchie, EPAD co-coordinator.
In the chosen nomenclature
-
V1500.0: V=version, “1500” is the number of sequentially recruited research participants in each dataset and ‘.0’ refers to the study visit the dataset includes up (visit 0 refers to the baseline data).
-
V500.0: V=version, “500” is the number of sequentially recruited research participants in each dataset and ‘.0’ refers to the study visit the dataset includes up (visit 0 refers to the baseline data).
The EPAD project has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° 115736, resources of which are composed of financial contribution from the European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA companies’ in kind contribution.